Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma

Expert Opinion on Emerging Drugs
Thomas D Rodgers, Patrick M Reagan

Abstract

The B-cell receptor (BCR) pathway is a crucial aspect of mature lymphocytes and is maintained in B-cell neoplasms. Many small module inhibitors targeting kinases within the BCR pathway are approved, with others in development, offering alternative treatment options to standard chemoimmunotherapy. Areas covered: This review covers both approved inhibitors and investigational inhibitors of spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), and phosphoinositide-3-kinase (PI3K) in the treatment of B-cell lymphomas. To collect relevant articles, a literature search was completed through the use of PubMed and abstracts from ASH and ASCO national meetings. Search terms including non-Hodgkin lymphoma, and BCR inhibitors, as well as the individual drug names, were utilized. The majority of included studies are dated from 2012 to March 2018. Expert opinion: BCR pathway inhibitors, such as ibrutinib and idelalisib, are novel treatments for non-Hodgkin lymphomas. While providing alternative treatment options to those with high-risk disease, poor functional status, and relapsed disease, outside of chronic lymphocytic leukemia (CLL), they have been limited to the relapsed/refractory setting. Their mechanisms of action, off/on-targ...Continue Reading

References

Jan 12, 1999·The Journal of Clinical Investigation·J L ClementsG A Koretzky
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Apr 24, 2002·Immunity·Attila MócsaiClifford A Lowell
Apr 2, 2005·Nature Reviews. Cancer·Ralf Küppers
Aug 19, 2006·Current Treatment Options in Oncology·Thomas E Witzig, Scott H Kaufmann
May 8, 2007·Proceedings of the National Academy of Sciences of the United States of America·James D ChangLewis C Cantley
Jan 30, 2008·The Lancet Oncology·Michael PfreundschuhUNKNOWN German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Oct 22, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Caylib A DurandMichael R Gold
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David GonzalezGareth J Morgan
Aug 10, 2012·The New England Journal of Medicine·H C Kluin-NelemansM H Dreyling
Aug 31, 2012·The New England Journal of Medicine·Steven P TreonZachary R Hunter
Oct 2, 2012·Blood·Kacey L SachenRonald Levy
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Mar 2, 2013·Nature Reviews. Drug Discovery·Ryan M Young, Louis M Staudt
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jan 24, 2014·The New England Journal of Medicine·Ajay K GopalGilles A Salles
May 30, 2014·The New England Journal of Medicine·Richard R FurmanY Lynn Wang
Aug 27, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brad S KahlSandra J Horning

❮ Previous
Next ❯

Citations

Mar 16, 2019·Immunological Reviews·Stefano CasolaFabio Facchetti
Apr 21, 2019·Cytopathology : Official Journal of the British Society for Clinical Cytology·Immacolata CozzolinoPio Zeppa
Nov 30, 2019·Hematological Oncology·Francesco PiazzaGianpietro Semenzato
Nov 9, 2019·Blood Reviews·Rossana MaffeiRoberto Marasca

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.